610-37-7

Usage

Uses

Used in Organic Synthesis:
5-Hydroxy-2-nitrobenzoic acid is used as a key intermediate for the synthesis of various organic compounds, contributing to the development of new chemical entities and materials.
Used in Pharmaceutical Industry:
5-Hydroxy-2-nitrobenzoic acid is used as a building block in the production of pharmaceuticals, playing a crucial role in the synthesis of drugs and medications.
Used in Agrochemical Industry:
5-Hydroxy-2-nitrobenzoic acid is used as a raw material in the formulation of agrochemicals, such as pesticides and herbicides, to improve agricultural productivity and crop protection.
Used in Dye Industry:
5-Hydroxy-2-nitrobenzoic acid is used as a precursor in the production of dyes, contributing to the development of new colorants for various applications, including textiles and plastics.

InChI:InChI=1/C7H5NO5/c9-4-1-2-6(8(12)13)5(3-4)7(10)11/h1-3,9H,(H,10,11)

Upstream product

• 623-11-0 1-methyl-4-nitrosobenzene 
• 610-28-6 2,5-dinitrobenzoic acid 
• 42454-06-8 2-nitro-5-hydroxybenzaldehyde 
• 13280-60-9 5-amino-2-nitrobenzoic acid 
• 99-06-9 3-Carboxyphenol 
• 7697-37-2 nitric acid 
• 98-95-3 nitrobenzene 
• 7732-18-5 water 
• 4368-83-6 2-nitro-5-acetylaminobenzoic acid 
• 142010-16-0 2-Nitro-5-hydroxycinnamic acid 
• 1882-69-5 5-methoxy-2-nitro-benzoic acid 
• 50594-66-6 acifluorfen 
• 2516-95-2 5-chloro-2-nitrobenzoic acid 
• 394-31-0 2-amino-5-hydroxybenzoic acid 

Downstream Products

• 394-31-0 2-amino-5-hydroxybenzoic acid 
• 59216-77-2 methyl 5-hydroxy-2-nitro-benzoate 
• 108129-56-2 5-hydroxy-2-ureido-benzoic acid 
• 68701-49-5 isopropyl 5-isopropoxy-2-nitrobenzoate 
• 117207-68-8 tert-butyl 5-hydroxy-2-nitrobenzoate 
• 78361-09-8 5-(1-Butyloxy)-2-nitrobenzoic acid 
• 1007374-30-2 C₂₉H₃₆F₃N₃O₆ 
• 1007374-28-8 C₂₆H₃₀F₃N₃O₆ 

Relevant academic research and scientific papers

Synthesis, properties, and remarkable 2 D self-assembly at the liquid/solid interface of a series of triskele-shaped 5,11,17-triazatrinaphthylenes (TrisK)

A series of 5,11,17-triazatrinaphthylene (TrisK) derivatives, large disk-like π-conjugated molecules with C3h symmetry, has been synthesised by following an optimised synthetic pathway. The synthesis was performed by a four-step protocol based

METHOD FOR SPECIFIC CLEAVAGE OF C Alpha-C BOND AND SIDE CHAIN OF PROTEIN AND PEPTIDE, AND METHOD FOR DETERMINING AMINO ACID SEQUENCE

The present invention provides a method for specifically cleaving a Cα-C bond of a peptide backbone and/or a side chain of a protein and a peptide, and a method for determining amino acid sequences of protein and peptide. A method for specifically cleaving a Cα-C bond of a peptide backbone and/or a side chain bond of a protein or a peptide, comprising irradiating a protein or a peptide with laser light in the presence of at least one hydroxynitrobenzoic acid selected from the group consisting of 3-hydroxy-2-nitrobenzoic acid, 4-hydroxy-3-nitrobenzoic acid, 5-hydroxy-2-nitrobenzoic acid, 3-hydroxy-5-nitrobenzoic acid, and 4-hydroxy-2-nitrobenzoic acid. A method for determining an amino acid sequence of a protein or a peptide, comprising irradiating a protein or a peptide with laser light in the presence of the above specific hydroxynitrobenzoic acid to specifically cleave a Cα-C bond of a peptide backbone and/or a side chain bond, and analyzing generated fragment ions by mass spectrometry.

Preparation technology of 6-hydroxy-bentazone

The invention discloses a preparation technology of 6-hydroxy-3-isopropyl-1H-benzo[c][1,2,6]thiadiazine-4(3H)-keto-2,2-dioxide. The preparation technology includes subjecting 5-chloro-2-nitrobenzoic acid serving as a raw material to hydrolysis reaction an

HETEROCYCLIC COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF

The present invention provides a heterocyclic compound represented by the formula (I), its stereoisomers, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and their use in preparing a medicament for the prevention and/or treatment of central nervous system disease.

A practical approach for regioselective mono-nitration of phenols under mild conditions

Cu(NO3)2.3H2O was demonstrated to be an efficient, regioselective and inexpensive nitrating reagent for the synthesis of mono-nitro substituted phenolic compounds. 12 examples of different phenols were examined. Good yields (67-90%) have been achieved. ARKAT-USA, Inc.

Supramolecular oxidation of anilines using hydrogen peroxide as stoichiometric oxidant

6A,6D-Di-O-(propan-2-on-1,3-diyl) α-cyclodextrin-6A,6D-dicarboxylate (2α) and 6A,6D-di-O-(propan-2-on-1,3-diyl) β-cyclodextrin-6A,6D-dicarboxylate (2β) were found to catalyze the oxidation of aromatic amines in the presence of hydrogen peroxide. The products were the corresponding nitro compounds or in some cases azo-, azoxy-, or other dimerization products. The catalysis was found to follow enzyme kinetics giving a rate increase (kcat/kuncat) of up to 1100 in the best case. Copyright

Nitrophenol derivatives oxidized by cerium(IV) ammonium nitrate (CAN) and their cytotoxicity

Oxidation of a series of phenols with cerium(IV) ammonium nitrate (CAN) in acetonitrile undermild conditions yields the mixture of corresponding nitrophenols. In the cases of methylphenols and hydroxy-carboxylic acids, the steric effect may reduce the nitration reaction. Compounds 3 a and 4b showed selective activities to Hep 3B and Hep G2 cancer cell lines, respectively. Compound 2c showed selective activities to Hep G2 and MDA-MB-231 cancer cell lines. Further more, com pound 10b showed selective activities to Hep G2, Hep 3B, MCF-7 and MDA-MB-231 cancer cell lines.

1H-IMIDAZO[4,5-c]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES

The invention relates to the use of imidazoquinolines and salts thereof in the treatment of protein kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, imidazoquinolines for use in the treatment of protein kinase dependent diseases, a method of treatment against said diseases, comprising administering the imidazoloquinolines to a warm-blooded animal, especially a human, pharmaceutical preparations comprising an imidazoquinoline, especially for the treatment of a protein kinase dependent disease, novel imidazoquinolines, and a process for the preparation of the novel imidazoquinolines.

An expedient synthesis of 7-O-functionalised pyrrolo[2,1-c][1,4]benzodiazepine-5,11-diones

An efficient synthetic route to 7-hydroxypyrrolo[2,1-c][1,4]benzodiazepine-5,11-dione, an important potential ligand for the DNA minor groove, has been developed. Simultaneous reduction of nitro and hydrogenolysis of the O-benzyl in N-(5-benzyloxy-2-nitro

Photochemical transformation of acifluorfen under laboratory and natural conditions

Acifluorfen was irradiated in pure water at various excitation wavelengths and pH values. Numerous photoproducts were obtained which were identified by [1H]NMR and /or HPLC-MS/MS. The main reaction pathways were photo-decarboxylation, photo-cleavage of the ether bonding with formation of phenolic compounds, photo-dechlorination and photo-Claisen type rearrangement. Decarboxylation was observed in acidic and neutral media whereas cleavage of the ether bonding dominated in basic media. The photo-Claisen type rearrangement only occurred on excitation at short wavelengths. The quantum yield of photolysis was significantly lower at 313nm (6.1 × 10-5) than at 254nm (2.0 × 10-3). The photoreactivity of acifluorfen was then studied in conditions approaching environmental conditions. Acifluorfen was dissolved in pure water, in water containing humic substances or in a natural water, and exposed to solar light in June at Clermont-Ferrand (latitude 46°N). In pure water, the half-life was estimated at 10 days and photo-decarboxylation accounted for 30% of the conversion. The presence of humic substances (10mg litre-1) did not affect the rate of photo-transformation. However, the half-life of acifluorfen dissolved in the natural water was only 6.8 days.